Findings

What do systematic reviews say?

1,835 questions · 1,886 findings · 74 reviews · Skin

Sort:Best matchNewestHighest certainty Download CSV

No studies found 542 · 28.7%GRADE not reported 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%

Hypnotherapy vs control

Severity of attack of recurrent herpes labialis during use of the preventative intervention (change in intensity) · participants with recurrent herpes labialis

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Hypnotherapy vs control

Change in severity (pain) of herpes labialis · participants with recurrent herpes labialis

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Hypnotherapy vs control

Change in severity (impairment of appearance) of herpes labialis · participants with recurrent herpes labialis

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Oral aciclovir (long‐term) vs placebo

Duration of attack of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis

1 finding from 1 review

Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

SLNB vs observation

Overall Survival Intention‐to‐treat Death from any cause during the study · patients with localised primary cutaneous melanoma

SLNB showed no clear difference in overall Survival Intention‐to‐treat Death from any cause during the… compared with observation (low certainty).

1 finding from 1 review

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma 2015 · Cochrane Headline outcomes only
HR 0.99 [0.82, 1.19]
1 study · 1661 participants
Low

Surgical Morbidity (Within 30 d) Related to the Regional Nodal Basin in Patients Assigned to the 2 Treatment Arms of MSLT‐I Any complication in the dissected basin, regional or systemic related to the surgical treatment in the regional nodal basin · patients with localised primary cutaneous melanoma

SLNB may leads to higher surgical Morbidity (Within 30 d) Related to the Regional Nodal Basin… compared with observation (low certainty).

1 finding from 1 review

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma 2015 · Cochrane Headline outcomes only
RR 14.36 [6.74, 30.59]
1 study · 1735 participants
Low

SLNB vs observation

Surgical Morbidity (Within 30 d) Related to Wide Excision of the Primary Site in Patients Assigned to the 2 Treatment Arms of MSLT‐I Any Surgical Complication related to the wide excision site · patients with localised primary cutaneous melanoma

SLNB showed no clear difference in surgical Morbidity (Within 30 d) Related to Wide Excision of the… compared with observation (low certainty).

1 finding from 1 review

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma 2015 · Cochrane Headline outcomes only
RR 1.11 [0.9, 1.37]
1 study · 1735 participants
Low

SLNB vs observation

Disease‐specific Survival Death from melanoma · patients with localised primary cutaneous melanoma

SLNB showed no clear difference in disease‐specific Survival Death from melanoma compared with observation (low certainty).

1 finding from 1 review

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma 2015 · Cochrane Headline outcomes only
HR 0.92 [0.74, 1.14]
1 study · 1661 participants
Low

SLNB vs observation

Disease‐free Survival First pathologically confirmed recurrence · patients with localised primary cutaneous melanoma

SLNB may leads to lower disease‐free Survival First pathologically confirmed recurrence compared with observation (low certainty).

1 finding from 1 review

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma 2015 · Cochrane Headline outcomes only
HR 0.75 [0.63, 0.89]
1 study · 1661 participants
Low

SLNB vs observation

Locoregional recurrence · patients with localised primary cutaneous melanoma

SLNB may leads to lower rate of pathologically confirmed locoregional recurrence following… compared with observation (low certainty).

1 finding from 1 review

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma 2015 · Cochrane Headline outcomes only
RR 0.56 [0.45, 0.69]
1 study · 1661 participants
Low

SLNB vs observation

Rate of development of distant metastases following SLNB and curative CLND First pathologically confirmed distant metastasis · patients with localised primary cutaneous melanoma

SLNB may leads to higher rate of development of distant metastases following SLNB and… compared with observation (low certainty).

1 finding from 1 review

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma 2015 · Cochrane Headline outcomes only
RR 1.33 [1.03, 1.72]
1 study · 1661 participants
Low

Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg

Participant‐reported improvement of hirsutism ‐ not measured · patients with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Flutamide 250 mg b.i.d. vs placebo

Proportion of participants who reported an adverse event · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 60 participants
Very low

Flutamide 250 mg b.i.d. vs placebo

Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 60 participants
Very low

Flutamide 250 mg b.i.d. vs placebo

Change in serum androgen levels · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 60 participants
Low

Flutamide 250 mg b.i.d. vs placebo

Change in BMI · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Flutamide 250 mg b.i.d. vs placebo

Improvement of other clinical signs of hyperandrogenism Mean number of menses in previous 6 months Scale from: 0 to 6 · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism

Flutamide 250 mg once to b.i.d. showed no clear difference in participant‐reported improvement of hirsutism 4‐point Likert scale compared with spironolactone 100 mg (low certainty).

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
RR 2 [0.88, 4.54]
1 study · 20 participants
Low

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Proportion of participants who reported an adverse event · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 40 participants
Low